Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy found that ...
ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line ...
ELF3 axis enables luminal progenitor transformation in BRCA1-deficient breast cancer by reducing genomic instability and promoting progenitor identity.
Researchers at the University of British Columbia (UBC), BC Cancer, Harvard Medical School and Memorial Sloan Kettering Cancer Center (MSK) have pinpointed what could be the early genetic origins of ...
Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA test results from 450 prostate cancer specimens. The findings suggest that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results